Current Coverage Archives

Discover IN8bio’s Potentially Breakthrough Next Generation γδ T cell-based T cell engager (TCE) Platform At AACR 2025 – $INAB $IBB $XBI $SNY

by John F. Heerdink, Jr. April 1, 2025 861Views 0Likes

IN8bio, Inc. (Nasdaq: INAB) , a trailblazer in gamma-delta T cell-based therapies, is turning heads at the forefront of cancer immunotherapy with its latest preclinical findings. Just this week, the company unveiled a poster presentation on its potentially breakthrough next generation…

Discover GeoVax’s Innovative Technologies For MPOX, Cancers & Beyond – ( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. March 11, 2025 412Views 0Likes

GeoVax Labs, Inc. (NASDAQ: GOVX), a clinical-stage biotechnology company, is developing innovative vaccines and immunotherapies against infectious diseases and cancers using proprietary platforms, with six ongoing clinical trials and a pipeline of preclinical programs targeting significant unmet medical needs. GeoVax's…

Jazz Pharmaceuticals’ Chimerix Acquisition Marks Significant Milestone In Precision Neuro-Oncology – ( $JAZZ $CMRX $LTRN )

by John F. Heerdink, Jr. March 6, 2025 423Views 0Likes

Jazz Pharmaceuticals' (NASDAQ: JAZZ) $935 million acquisition of Chimerix (NASDAQ: CMRX) marks a significant milestone in precision neuro-oncology, highlighting the growing potential of targeted therapies for brain cancers and signaling a shift towards biomarker-driven approaches in treating central nervous system tumors. The…

Summary of 5 Top US Stock Performers and Relevant News For Wednesday, Feb. 19 – $COMP $HIMS $FRSH $GE $NVMI

by John F. Heerdink, Jr. February 19, 2025 277Views 0Likes

On February 19, 2025, several stocks demonstrated remarkable performance, with Compass, Inc. (COMP) and Hims & Hers Health, Inc. (HIMS) leading the pack. Here's a summary of the top performers and relevant news: Compass, Inc. (COMP) surged 28.32% to $10.24. The company…

A Beacon of Hope Has Emerged For Leukemia Patients From The Labs of IN8bio, Inc. (NASDAQ: INAB)

by John F. Heerdink, Jr. February 11, 2025 392Views 0Likes

In the realm of cutting-edge cancer therapeutics, a beacon of hope has emerged from the laboratories of IN8bio, Inc. (NASDAQ: INAB) . This clinical-stage biopharmaceutical company has recently unveiled promising results from its ongoing Phase 1 clinical trial of INB-100, a groundbreaking…

Indaptus Emerging With Potential Keytruda Partner or Competitor – ( $MRK $INDP $IBB )

by John F. Heerdink, Jr. February 10, 2025 435Views 0Likes

Indaptus Therapeutics (NASDAQ: INDP) , a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, has received approval from Health Canada to expand its clinical trial of Decoy20, a promising cancer treatment, into Canada, broadening patient recruitment for its ongoing U.S.-based…

Beta Bionics Upsizes IPO On Thursday As Insulin Pump Market Sees Innovation Surge – $BBNX $MODD

by Vista Partners LLC January 30, 2025 437Views 0Likes

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The…

Insulin Pump Market Experiencing Innovation Surge – Beta Bionics Upsized IPO – Modular Medical FDA Clearance – $BBNX $MODD

by Vista Partners LLC January 28, 2025 368Views 0Likes

The insulin pump market is experiencing a surge of innovation, with Beta Bionics targeting a $695 million valuation in its upsized IPO and Modular Medical receiving FDA clearance for its user-friendly MODD1 insulin pump, promising improved accessibility and management options for diabetes…

Elon Musk’s xAI’s Record-Breaking Star-Studded Funding – $TSLA $NVDA $AMD $SPY

by Vista Partners LLC January 1, 2025 1597Views 0Likes

Based on reports from Business Insider, Elon Musk's artificial intelligence company xAI has secured a staggering $6 billion in Series C funding, propelling its valuation to over $40 billion and positioning it as a major player in the competitive AI landscape. Yes…

Current Coverage

Your Guide To Staying Informed In The Markets